Predicting Oncotype DX recurrence scores using clinicopathologic features: Tennessee University Nomogram: An external validation

The 21 gene recurrence score (RS) assay, Oncotype Dx (ODX) was developed to predict the benefits of chemotherapy in hormonal receptor (HR) positive early breast cancer (EBC). The Tennessee University Nomogram (UTMC), based on clinic-pathologic features (tumor grade, progesterone receptor, histologic type and age). estimate the probability that a patient's (p) with EBC (stage I-II), has a low-risk (LR 1-25) or a high-risk (HR-26-100) ODX-RS in female (p) >50 years old; in ≤50 years old, is applicable only for estimation of the probability for a HR-ODX RS.